Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04867434 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of RZL-012 on Submental Fat Reduction
A Phase 2 study of Submental Fat, sponsored by Raziel Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
- 1
- Study location
NCT04867434 is a Phase 2 study of Submental Fat that has completed, run by Raziel Therapeutics. The registered enrollment target is 151 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04867434, a Phase 2 study of Submental Fat, has completed, sponsored by Raziel Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
- 1
- Study location
Study Summary
A total of 135 eligible male or female subjects will be randomized according to a predetermined randomization scheme (1:1:1 ratio) to receive a single multi-injection treatment of high dose RZL-012, low dose RZL-012, or placebo on Day 0. They will be monitored for safety and efficacy over 84 days.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RZL-012
Study Locations (1)
Illinois
- DenovaResearch - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2021-06-15 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04867434
The ClinicalTrials.gov registry entry for NCT04867434 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Raziel Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Submental Fat appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04867434 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04867434 about?
NCT04867434 is a clinical study titled "Efficacy and Safety of RZL-012 on Submental Fat Reduction". A total of 135 eligible male or female subjects will be randomized according to a predetermined randomization scheme (1:1:1 ratio) to receive a single multi-injection treatment of high dose RZL-012, low dose RZL-012, or placebo on Day 0. They will be monitored for safety and efficacy over 84 days.
What is the current status of trial NCT04867434?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2021-06-15. Estimated completion is 2022-05-31.
What conditions does trial NCT04867434 study?
This clinical trial studies the following conditions: Submental Fat.
What interventions are being tested in trial NCT04867434?
The interventions under investigation include: Placebo (DRUG), RZL-012 (DRUG).
Who is sponsoring clinical trial NCT04867434?
This trial is sponsored by Raziel Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04867434 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Submental Fat
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.